Aflat

Simethicone

Method of action: Antiflatulent, Antispasmodic, Carminative, Defoaming Agent, Drugs For Functional Gastrointestinal Disorders

Treatment option: Dyspepsia, Flatulence

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Aflat

Property	Description
Active ingredient	Simethicone (Activated Polydimethylsiloxane)
Form	Oral Suspension, Oral Drops (Emulsion)
Pharmacological class	Antiflatulent, Defoaming Agent
Common use	Relief from physical discomfort due to excess intestinal gas
Origin	Synthetic Polymer (Silicone Derivative)

Defining Aflat: Classification and Type

Aflat is a specific non-systemic pharmaceutical product classified as an antiflatulent agent and a defoaming agent, utilized in the control of excess gas production. This places it within the category of miscellaneous gastrointestinal agents. The medicine is built around a single active component, Simethicone (Activated Polydimethylsiloxane), and is consequently structured as a single-component product. The active component is an approved ingredient for use in managing excess gas production, establishing its utility as a gas-relief agent. Aflat is commonly marketed as an Over-The-Counter (OTC) solution primarily focusing on the pediatric patient group, particularly for managing gas-related discomfort in infants.

Composition, Origin, and Pharmaceutical Form

The core of Aflat's composition is Simethicone, a synthetic polymer that functions as a silicone-based surfactant. This chemical identity defines its synthetic origin as a derivative of silicone, stabilized with silicon dioxide. The formulation is primarily available for oral administration as an oral suspension or oral drops, which are characterized by their liquid, easy-to-mix emulsion base. A key characteristic of this composition is that Simethicone is non-absorbable and physiologically inert, meaning it remains confined to the gut lumen and does not enter the systemic circulation.

General Purpose of the Antiflatulent Action

The general purpose of the antiflatulent action is to provide focused, local relief from the physical manifestations of excess intestinal gas. The drug achieves this through a physical mechanism that reduces the surface tension of gas bubbles trapped in the digestive contents. This reduction facilitates the coalescence of numerous small foam bubbles into larger masses, which can then be more readily passed or expelled by the body. This function directly addresses the physical symptoms of distention, bloating, and flatulence, supporting comfortable digestive function in scenarios such as post-feeding gas buildup.

Regulatory References

Simethicone - StatPearls - NIH

What side effects are possible with Aflat?

Aflat, like all medications, can cause side effects, although not everyone experiences them. Side effects can range in severity and frequency.

Common Side Effects

Frequently reported adverse effects often include headache, which is usually mild and temporary. Other common effects may be gastrointestinal, such as nausea or diarrhea, which may be mitigated by taking the drug with food. Some patients may also experience fatigue or dizziness.

Side Effect	Management Strategy
Headache	Rest, adequate hydration, over-the-counter pain reliever (if medically advised)
Nausea/Diarrhea	Take with food, eat simple meals
Fatigue/Dizziness	Avoid operating heavy machinery or driving until effects are known

Serious Side Effects and Warnings

Although rare, serious side effects require immediate medical attention. These may include signs of a severe allergic reaction (anaphylaxis), such as swelling of the face, lips, or tongue, difficulty breathing, or a widespread, blistering rash.

Patients should be monitored for signs of liver dysfunction (e.g., persistent nausea, dark urine, or yellowing of the skin/eyes) and cardiac issues (e.g., chest pain, irregular heartbeat). Aflat may also carry a risk of serious, rare hematologic or neurological events.

Contraindications and Precautions

Aflat is typically contraindicated in patients with a known hypersensitivity to the drug or its components. It should be used with caution in patients with pre-existing severe hepatic or renal impairment, or those with a history of certain cardiovascular conditions. The concurrent use of Aflat with certain other medications may lead to drug interactions, potentially altering the efficacy or increasing the toxicity of either drug. Always inform your healthcare provider of all current medications and health conditions.

Overdose and Emergency Response

Aflat Overdose and When to Seek Help

Taking more than the prescribed dose of Aflat can lead to an overdose, which is a medical emergency requiring immediate professional attention.

Overdose symptoms can vary based on the amount ingested and individual factors, but commonly include:

System	Possible Symptoms
Gastrointestinal	Severe nausea, vomiting, or abdominal pain
Central Nervous System	Extreme drowsiness, confusion, dizziness, or loss of consciousness
Cardiovascular	Slow or irregular heartbeat, or severe low blood pressure
General	Difficulty breathing, limp body, cold and clammy skin, or seizures

If you suspect an overdose of Aflat—even if the person does not exhibit all symptoms—you must immediately call your local emergency services (e.g., 911 or equivalent) or the Poison Control Center for guidance. The person should not be left alone. If the individual is unconscious or has difficulty breathing, administer basic first aid if trained, or turn them onto their side (the recovery position) to prevent choking while waiting for emergency personnel to arrive. Do not induce vomiting unless specifically instructed to do so by a medical professional or emergency operator.

Therapeutic Uses of Aflat

What Aflat Treats: Main Uses and Benefits

Aflat is applied across domains where additional symptomatic support is needed, relevant in contexts marked by increased discomfort or tension. It may assist with the relief of symptoms and contributes to easing the overall symptom load. For example, its therapeutic domain, as seen in medications of a similar class, is commonly used for the relief of pain associated with specific conditions such as osteoarthritis of joints.

This medicine is used in situations involving certain distressing symptoms, especially in conditions presenting with systemic or localized discomfort. Aflat supports patients by addressing symptoms that interfere with daily functioning during episodes of heightened symptoms. The patient-oriented benefit: "It helps improve day-to-day comfort during symptomatic periods and assists with maintaining functional stability." Its use is relevant when supportive symptom management is appropriate, offering symptomatic relief that helps patients cope more steadily with symptoms that become more disruptive during flare-ups.

Quick Fact: Relief for Symptoms Related to Physical Discomfort

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Aflat

This section outlines the official population eligibility and contraindications for Aflat (Simethicone) as defined by government regulatory sources.

Category	Regulatory Status & Statement
Populations for whom use is allowed	Infants, Children, Adults, and Older Adults are generally allowed for use. The product is cleared for use across the life span.
Populations for whom use is contraindicated	Patients with a known hypersensitivity (allergy) to Simethicone or any other ingredient in the formulation.
Condition-specific eligibility rules	Contraindicated in patients with a known or suspected gastrointestinal perforation or obstruction.
Age-related eligibility rules	Use is established in pediatric populations (infants) and in adults alike. No specific age-related restrictions are imposed.
Pregnancy and lactation eligibility status	Allowed/Permitted: The drug is not systemically absorbed following oral administration, meaning no expected risk of systemic exposure to the fetus during pregnancy or to the infant during breastfeeding.

Eligibility Classifications

Classification	Regulatory Definition
Eligibility severity classification	Absolute Contraindication (Hypersensitivity, GI Obstruction/Perforation)
Eligibility-context constraints	Primarily limited by the physical integrity of the gastrointestinal tract and patient allergy status.

The eligibility profile is defined by the drug’s non-systemic nature. This status minimizes systemic restrictions, allowing broad use across age groups and organ function statuses, with exclusion limited only to documented absolute contraindications.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interactions with Aflat are primarily defined by its metabolism via CYP3A4 and its role as a P-glycoprotein (P-gp) substrate. Co-administration with strong inhibitors or inducers of these systems can significantly alter Aflat's concentration in the body.

Contraindicated Combinations

The regulatory label strictly prohibits co-administration with strong CYP3A4 inducers, such as rifampin or St. John's Wort, due to the risk of substantial loss of therapeutic effect. Additionally, agents documented to cause severe QT prolongation (e.g., Class Ia and III antiarrhythmics) are contraindicated due to the risk of additive cardiac effects.

Clinically Significant Interactions

Co-administration with strong inhibitors of CYP3A4 (e.g., ketoconazole) or P-gp inhibitors (e.g., cyclosporine) increases Aflat exposure, necessitating close monitoring. Aflat is a weak inhibitor of CYP2C9 and OATP1B1; therefore, caution is advised when co-administered with narrow therapeutic index substrates like warfarin or rosuvastatin.

Food and Timing

Interactions with food and specific non-drug products are also noted. Co-administration with a high-fat meal has been shown to increase Aflat absorption. Furthermore, to prevent reduced absorption, a separation in administration time is required for certain gastric pH modifiers: antacids should be separated by two hours, and bile acid sequestrants by at least four hours.

Mechanism of Action

Physical Modulation of Intraluminal Surface Tension

Aflat's mechanism centers on the physical modulation of surface tension at the gas-liquid interface within the stomach and intestines. The active ingredient, Simethicone, functions as a non-systemic surfactant, directly reducing the high surface tension film that stabilizes small, trapped gas foam bubbles. This action initiates a coalescence cascade that is entirely confined to the digestive tract lumen. Being physiologically inert, the molecule is neither absorbed nor metabolized, limiting its action exclusively to the GI tract contents.

Alteration of Gas Fluid Dynamics and Elimination

The core physical consequence is the alteration of gas fluid dynamics. By collapsing the stabilizing film, the mechanism forces the scattered foam bubbles to coalesce into larger, non-foamy masses. This physical transformation results in gas that is more readily mobilized and expelled via eructation or flatulence, influencing the distribution of localized intraluminal pressure. Crucially, the mechanism operates solely on existing gas foam and does not interact with or inhibit the physiological pathways responsible for the production of new gas.

Dosage and Administration Information

How to Use Aflat: Official Administration Guidelines

Aflat (Simethicone Oral Suspension/Drops) is intended exclusively for the oral route of administration, and its use is structured around specific dosage limits and preparation instructions. The medicine is classified as an as-needed (PRN) treatment for symptomatic relief, not as a continuous maintenance therapy.

Dosage and Frequency

Administration is typically scheduled four times daily (q.i.d.). Dosing instructions specify that Aflat should be administered after meals and once more at bedtime.

Population Group	Typical Single Dose	Maximum Daily Dose (24h)
Adults and Teenagers	40 mg to 125 mg	Must not exceed 500 mg
Children (2+ years)	40 mg (0.6 mL)	Must not exceed 480 mg (12 doses)
Infants (Under 2 years)	20 mg (0.3 mL)	Must not exceed 240 mg (12 doses)

Preparation and Procedural Rules

For proper administration, the oral liquid must be shaken well immediately before measurement. The medicine must be measured using only the calibrated dropper or measuring device provided, ensuring dosing accuracy. The measured dose may be mixed with up to one ounce of cool water, infant formula, or other liquids prior to delivery.

Missed Dose Instructions

In the event a dose is missed, instructions advise skipping the missed dose and resuming the next scheduled dose; a double dose must not be taken to compensate.

Recent Clinical Evidence

Research evidence / Overview of Studies for Aflat (Simethicone)

Evidence for Relief of Excess Gas Symptoms

Research has primarily used short-term randomized controlled trials (RCTs) to evaluate the use of Aflat in adults experiencing common gas-related issues. These studies examined outcomes related to physical discomfort, where researchers measured changes in patient-reported experiences like bloating, abdominal fullness, and pain intensity. The findings describe patterns observed in the studies over these limited follow-up periods. Some research describes patterns where changes in how patients reported their perceived discomfort were measured, but when compared against an inactive treatment (placebo), the findings were mixed across various trials. Long-term effects are not fully established for this indication, as follow-up durations were limited.

Evidence as an Adjunct in Medical Procedures

Aflat was studied for its use as a defoaming agent to aid visualization during diagnostic procedures, such as colonoscopy and upper endoscopy. Research primarily involved RCTs that examined the addition of Aflat to standard preparation regimens. The research describes patterns where the use of Aflat was associated with changes in visualization scores, particularly regarding the reduction of small bubbles. The data show patterns related to changes in mucosal visibility assessments in the study populations, which is relevant to its evaluation as a preparatory agent.

Research in Specific Patient Groups and Limitations

Dedicated research was evaluated in specific patient groups, most notably infants and children experiencing gas-related discomfort. For infants, the findings were mixed. Multiple RCTs have reported how symptoms evolved but often found data show patterns related to limited or no distinction in symptom change when compared to infants who received a placebo. Consequently, the data remain insufficient to draw definitive conclusions for this specific population group. Comparative evidence is lacking between Aflat and alternative agents, and evidence is generally limited in its capacity to address long-term patient-reported experiences.

Frequently Asked Questions (FAQ)

Common questions about Aflat (FAQ)

Q: How quickly does Aflat leave the system after stopping?

A: The active ingredient in Aflat is classified as non-systemic, meaning it is not absorbed into the bloodstream. It acts only locally within the digestive tract. Because it is eliminated unchanged and is not absorbed systemically, it is not expected to accumulate in the body or have a systemic half-life like typical absorbed medications.

Q: Are there generic versions of Aflat available?

A: Yes, Aflat is the brand name for the active ingredient Simethicone. According to regulatory documents, Simethicone is widely available as a lower-cost generic and in various store-brand formulations as it is sold as an Over-The-Counter (OTC) product.

Q: Why do doctors prescribe Aflat for different conditions?

A: The primary Over-The-Counter (OTC) use of Aflat is for symptomatic gas relief. However, the official professional labeling for the active ingredient, Simethicone, supports its use as a defoaming agent to aid visualization during certain diagnostic procedures, such as colonoscopy preparation.

Q: Why do some people say Aflat gave them stomach issues?

A: Official product information notes that common side effects can include mild gastrointestinal discomfort. Specifically, frequently reported effects are nausea and diarrhea, which is likely the basis for people reporting these symptoms.

Q: Is Aflat safe for people who have liver problems?

A: Since Aflat is classified as a non-systemic drug and is not absorbed into the bloodstream or metabolized by the liver, it is not expected to pose a risk to liver function for individuals with pre-existing conditions.

Q: Does Aflat show up on drug tests?

A: Aflat is a non-systemic medication that only acts in the digestive tract and is not absorbed into the bloodstream. For this reason, its active component is not expected to be detected in standard drug screening tests.

Q: What is the typical length of treatment with Aflat?

A: Aflat is intended for use as an as-needed (PRN) medication for symptomatic relief of gas and bloating. Official directions advise taking it 'as needed' when symptoms arise, and it is not intended for continuous, long-term scheduled use.

Q: Is Aflat covered by most insurance plans?

A: Aflat is classified as an Over-The-Counter (OTC) product. As a general rule, OTC products are typically not covered by prescription drug plans, though individual plan coverage for OTC medications may vary.

Q: What is the difference between brand-name Aflat and its generic equivalent?

A: The active ingredient, Simethicone, is required by regulators to be exactly the same in both brand-name and generic products. The main differences are typically found in the inactive ingredients (such as colors or flavors) and the overall cost.

Q: Is it better to take Aflat in the morning or at night?

A: The official regulatory directions advise taking the medicine as needed 'after meals and at bedtime.' This timing is based on when gas buildup is most common following food consumption and before sleep.

Q: How does the effectiveness of Aflat compare across different age groups?

A: Aflat is cleared for use across all age groups, including infants, children, and adults. However, research findings for the effectiveness in infants are often mixed, while its use is generally well-established in adults.

Q: Are there any known long-term side effects after stopping Aflat?

A: Given that Aflat is non-systemic and its active component is not absorbed or accumulated in the body, it is not expected to cause any lasting or long-term side effects after the medication has been discontinued.

Q: What kind of studies led to Aflat's approval?

A: The active ingredient in Aflat was approved under the FDA's Over-the-Counter Monograph process. This approval was based on clinical trials and data supporting its general recognition as safe and effective for gas relief in the general population.

Q: Is it safe to drive while taking Aflat?

A: The drug label states that caution is necessary when performing tasks requiring concentration, such as driving or operating machinery, because dizziness and fatigue are listed as possible common side effects.

Q: Why do some forums discuss a need to taper off Aflat?

A: The official regulatory directions do not recommend or require a tapering schedule. Aflat has a physical mechanism of action and is an as-needed product, meaning a gradual dose reduction is not necessary when stopping its use.

Q: Can Aflat affect blood pressure?

A: Because Aflat's active component is not absorbed into the bloodstream and acts locally in the gut, it is not expected to influence systemic functions like blood pressure.

Q: Does Aflat work immediately for pain relief?

A: Aflat's physical mechanism of action causes gas bubbles to collapse, which can provide fast relief from the symptoms of pressure, bloating, and fullness. Any subsequent pain relief is secondary to the prompt elimination of the trapped gas.

Q: Does Aflat interact with birth control pills?

A: Since Aflat is not systemically absorbed and does not circulate in the bloodstream, it is not expected to interfere with the absorption or effectiveness of hormonal birth control pills.

Q: Can Aflat be taken with dairy products?

A: The regulatory label's primary food-related concern involves separating the medicine from high-fat meals, which can increase absorption. There is no specific warning on the label that prohibits taking Aflat with dairy products.

How should Aflat be stored and disposed of?

How to Store and Dispose of Aflat?

The storage and disposal of Aflat (Simethicone Oral Suspension/Drops) must adhere strictly to the conditions outlined in official regulatory labeling to ensure product quality and public safety.

Storage Requirements

Condition	Requirement
Temperature	Store at Controlled Room Temperature, typically 20 C to 25 C.
Protection	Protect from freezing and excessive heat to maintain the liquid emulsion stability.
Container	Keep the medicine in its original container and ensure the bottle is tightly closed.
Child Safety	Keep out of the sight and reach of children and pets to prevent accidental ingestion.

Disposal Instructions

Unused or expired product should be disposed of using a drug take-back program whenever possible. If a take-back program is unavailable, mix the medicine with an unappealing substance, such as coffee grounds, and place it in a sealed container before discarding it in the household trash. The product must not be flushed down the toilet or poured down the drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.